Waters and Labcorp to expand access to cervical cancer screening with BD Onclarity HPV assay

WAT•2026-10-23

Waters and Labcorp plan to offer the BD Onclarity HPV assay by the end of 2026, describing it as the most comprehensive FDA-approved HPV testing option.

1. Screening access plans

Waters and Labcorp plan to offer the BD Onclarity HPV assay by the end of 2026 to expand access to cervical cancer screening.

Waters and Labcorp to expand access to cervical cancer screening with BD Onclarity HPV assay

1. Screening access plans

Related News

Sierra Bancorp declares quarterly cash dividend of $0.27 per share

SLB tops estimates on resilient North America demand, sees Middle East rebound

Kaiser Aluminum: Wells Fargo cuts target price to $125 from $160

Steep bill for AI buildout punishes Meta, other tech favorites

US corporate profit boom faces its ‘Minsky moment’